Gene Patent Stoush Heads to US Court
By Karen Barlow,
ABC News [Australia]
| 12. 08. 2011
The fight over human genes and whether they can be patented for medical research has gone to the US Supreme Court.
The American Civil Liberties Union and the Public Patent Foundation filed their appeal on Thursday, arguing genes are products of nature and cannot be sequestered by private companies.
The case concerns Myriad Genetics, a biotech company that holds patents on two genes that can help reveal susceptibility to breast and ovarian cancer.
There is concern their monopoly position stymies research and restricts patient access to tests and treatment, but the biotech sector and patent lawyers say there are safeguards.
[Audio: Action filed to invalidate gene patents (PM)]
ANU visiting fellow and intellectual property law consultant Luigi Palombi says if a company has a patent on a gene, it can control everything that happens with that gene.
"You can control its use in research, you can control its use in the development of a medicine, you can control its use in the use of a diagnostic, etc.," he said.
"And yet all you've done is discovered a link between a...
Related Articles
By Holly Baxter, The Independent | 08.19.2025
In rural Pennsylvania, I’m hiking through the forest with Simone and Malcom Collins and discussing the executive order they wrote for Donald Trump. Just outside their house — beyond the chicken coop, where they gather their eggs for homemade cakes...
By Jacob Bogage, The Washington Post | 09.03.2025
The conservative group behind the Project 2025 governing playbook for President Donald Trump’s second term is set to propose sweeping revisions to U.S. economic policy meant to encourage married heterosexual couples to have more children.
The Heritage Foundation, a right-wing...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Tia Ghose, Live Science | 09.16.2025
Twenty-six years ago today, on Sept. 17, a teenager who had received an experimental gene therapy died. His death led to needed changes in the clinical trial process while also spurring skepticism that would ultimately stall the field of gene...